CNBC raises its Eli Lilly price target on Mounjaro and Zepbound growth
CNBC's investing team lifts its target on Lilly shares and argues the obesity drug run still has room to grow.
Recap by typeshit. Full story at CNBC.
Read at CNBC
More peptides
-
Semaglutide shifts Indian generic makers' plans as Torrent looks to Brazil Semaglutide shifts Indian generic makers' plans as Torrent looks to Brazil
The Pharma Letter looks at how semaglutide generics are changing strategy in India, with Torrent eyeing an expansion into Brazil.
-
Semafor notes few national politicians are talking about GLP-1 policy Semafor notes few national politicians are talking about GLP-1 policy
Semafor looks at how little national political figures have said about what the new class of weight loss drugs means for policy.
-
The Brain Docs rate statins and Ozempic in their wellness trends series 
The Brain Docs rate statins and Ozempic in their wellness trends series
The doctors take on two of the topics their followers ask about most, giving their verdict on statins and Ozempic.
-
CBS Mornings looks at influencers selling peptides as RFK Jr. backs them CBS Mornings looks at influencers selling peptides as RFK Jr. backs them
Social media promoters claim peptides speed healing, smooth skin and extend life, and CBS notes the HHS Secretary counts himself a fan.
-
GLEAM preprint asks whether GLP-1 drugs ease endometriosis beyond weight loss peptides typeshitResearchGLEAM preprint asks whether GLP-1 drugs ease endometriosis beyond weight loss
The new preprint looks at whether symptom relief people report on GLP-1 medications comes from weight loss alone or something else.
-
Lilly's retatrutide cut body weight about 20% to 21% over 80 weeks in a phase 3 trial 
peptides typeshitResearchLilly's retatrutide cut body weight about 20% to 21% over 80 weeks in a phase 3 trial
Lilly says participants lost 44 to 47 pounds versus about 21 on Ozempic, with bigger A1C drops. It plans to file for approval in 2027.
